Prescription drug prices paid under federal programs: analyses, differences, factors
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York
Nova Science Publishers
[2014]
|
| Schriftenreihe: | Health care in transition series
|
| Schlagworte: | |
| Beschreibung: | Includes index PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: PRESCRIPTION DRUGS: COMPARISON OF DOD, MEDICAID, AND MEDICARE PART DRETAIL REIMBURSEMENT PRICES; WHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; MEDICAID PAID LOWER NET PRICES THAN DOD ANDMEDICARE PART D, LARGELY DUE TO DIFFERENCES INPOST-PURCHASE PRICE ADJUSTMENTS; AGENCY COMMENTS; APPENDIX I: SCOPE AND METHODOLOGY. Chapter 2: PRESCRIPTION DRUGS: COMPARISON OF DOD AND VADIRECT PURCHASE PRICESWHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; DOD PAID A HIGHER AVERAGE DIRECT PURCHASEPRICE THAN VA ACROSS THE ENTIRE SAMPLE BUT PAIDLESS THAN VA FOR BRAND-NAME DRUGS; CONCLUDING OBSERVATIONS; AGENCY COMMENTS AND OUR EVALUATION; APPENDIX I: SCOPE AND METHODOLOGY; APPENDIX II: RELATIVE PRICES PAID BY DOD AND VAFOR THE 83 DRUGS IN THE DIRECT PURCHASE SAMPLE; Chapter 3: PRESCRIPTION DRUGS: OVERVIEW OF APPROACHES TO CONTROL PRESCRIPTION DRUG SPENDING IN FEDERAL PROGRAMS; WHY GAO DID THIS STUDY. WHAT GAO FOUNDBACKGROUND; FEHBP USES COMPETITION BETWEEN HEALTH PLANSTO CONTROL PRESCRIPTION DRUG COSTS; OTHER FEDERAL PROGRAMS USE A RANGEOF APPROACHES TO CONTROL PRESCRIPTIONDRUG SPENDING; Chapter 4: MEDICAID PRESCRIPTION DRUGS:CMS SHOULD IMPLEMENT REVISEDFEDERAL UPPER LIMITS AND MONITORTHEIR RELATIONSHIP TO RETAILPHARMACY ACQUISITION COSTS*; WHY GAO DID THIS STUDY; WHAT GAO RECOMMENDS; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; CMS DEVELOPS NADACS BY SURVEYING RETAILCOMMUNITY PHARMACIES FOR INVOICE DATA ONACTUAL ACQUISITION COSTS. First quarter 2013 ppaca-based fulswere nearly equal to nadacs across alldrugs in aggregate, but varied greatlyfor individual drugsconclusion; recommendation for executive action; agency comments and our evaluation; appendix i.methodology for comparingfederal upper limits to national averagedrug acquisition costs; appendix ii. comparison of federalupper limits to national average drugacquisition costs, top 50medicaidexpenditure drugs; appendix iii. comparison of federal upper limitsto national average drug acquisition costs, top50medicaid utilization drugs APPENDIX IV. 3-MONTH ROLLING AVERAGE FEDERALUPPER LIMITS COMPARED WITH NATIONAL AVERAGEDRUG ACQUISITION COSTSBlank Page; INDEX. In 2011, federal spending for prescription drugs by DOD, Medicaid, and Medicare Part D totaled 71.2 billion-representing about 85 percent of all federal prescription drug expenditures-for about 114.4 million beneficiaries. Each program reimbursed retail pharmacies for outpatient prescriptions filled at these pharmacies by their beneficiaries. This book compares retail reimbursement prices paid by DOD, Medicaid, and Medicare Part D for a sample of prescription drugs and describes factors affecting these prices. It also discusses approaches to control prescription drug spending in federal progra |
| ISBN: | 9781634634151 1634634152 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044357092 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170620s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9781634634151 |9 978-1-63463-415-1 | ||
| 020 | |a 1634634152 |9 1-63463-415-2 | ||
| 035 | |a (ZDB-4-NLEBK)ocn899276755 | ||
| 035 | |a (OCoLC)899276755 | ||
| 035 | |a (DE-599)BVBBV044357092 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615.1 |2 23 | |
| 245 | 1 | 0 | |a Prescription drug prices paid under federal programs |b analyses, differences, factors |c edited by Suzanna Elwin |
| 264 | 1 | |a New York |b Nova Science Publishers |c [2014] | |
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Health care in transition series | |
| 500 | |a Includes index | ||
| 500 | |a PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: PRESCRIPTION DRUGS: COMPARISON OF DOD, MEDICAID, AND MEDICARE PART DRETAIL REIMBURSEMENT PRICES; WHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; MEDICAID PAID LOWER NET PRICES THAN DOD ANDMEDICARE PART D, LARGELY DUE TO DIFFERENCES INPOST-PURCHASE PRICE ADJUSTMENTS; AGENCY COMMENTS; APPENDIX I: SCOPE AND METHODOLOGY. | ||
| 500 | |a Chapter 2: PRESCRIPTION DRUGS: COMPARISON OF DOD AND VADIRECT PURCHASE PRICESWHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; DOD PAID A HIGHER AVERAGE DIRECT PURCHASEPRICE THAN VA ACROSS THE ENTIRE SAMPLE BUT PAIDLESS THAN VA FOR BRAND-NAME DRUGS; CONCLUDING OBSERVATIONS; AGENCY COMMENTS AND OUR EVALUATION; APPENDIX I: SCOPE AND METHODOLOGY; APPENDIX II: RELATIVE PRICES PAID BY DOD AND VAFOR THE 83 DRUGS IN THE DIRECT PURCHASE SAMPLE; Chapter 3: PRESCRIPTION DRUGS: OVERVIEW OF APPROACHES TO CONTROL PRESCRIPTION DRUG SPENDING IN FEDERAL PROGRAMS; WHY GAO DID THIS STUDY. | ||
| 500 | |a WHAT GAO FOUNDBACKGROUND; FEHBP USES COMPETITION BETWEEN HEALTH PLANSTO CONTROL PRESCRIPTION DRUG COSTS; OTHER FEDERAL PROGRAMS USE A RANGEOF APPROACHES TO CONTROL PRESCRIPTIONDRUG SPENDING; Chapter 4: MEDICAID PRESCRIPTION DRUGS:CMS SHOULD IMPLEMENT REVISEDFEDERAL UPPER LIMITS AND MONITORTHEIR RELATIONSHIP TO RETAILPHARMACY ACQUISITION COSTS*; WHY GAO DID THIS STUDY; WHAT GAO RECOMMENDS; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; CMS DEVELOPS NADACS BY SURVEYING RETAILCOMMUNITY PHARMACIES FOR INVOICE DATA ONACTUAL ACQUISITION COSTS. | ||
| 500 | |a First quarter 2013 ppaca-based fulswere nearly equal to nadacs across alldrugs in aggregate, but varied greatlyfor individual drugsconclusion; recommendation for executive action; agency comments and our evaluation; appendix i.methodology for comparingfederal upper limits to national averagedrug acquisition costs; appendix ii. comparison of federalupper limits to national average drugacquisition costs, top 50medicaidexpenditure drugs; appendix iii. comparison of federal upper limitsto national average drug acquisition costs, top50medicaid utilization drugs | ||
| 500 | |a APPENDIX IV. 3-MONTH ROLLING AVERAGE FEDERALUPPER LIMITS COMPARED WITH NATIONAL AVERAGEDRUG ACQUISITION COSTSBlank Page; INDEX. | ||
| 500 | |a In 2011, federal spending for prescription drugs by DOD, Medicaid, and Medicare Part D totaled 71.2 billion-representing about 85 percent of all federal prescription drug expenditures-for about 114.4 million beneficiaries. Each program reimbursed retail pharmacies for outpatient prescriptions filled at these pharmacies by their beneficiaries. This book compares retail reimbursement prices paid by DOD, Medicaid, and Medicare Part D for a sample of prescription drugs and describes factors affecting these prices. It also discusses approaches to control prescription drug spending in federal progra | ||
| 650 | 4 | |a Drugs / Prices | |
| 650 | 4 | |a Health status indicators | |
| 650 | 4 | |a Prescription pricing | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Medical care, Cost of |2 fast | |
| 650 | 7 | |a Prescription pricing |2 fast | |
| 650 | 7 | |a Prescription pricing / Government policy |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Politik | |
| 650 | 4 | |a Prescription pricing |z United States | |
| 650 | 4 | |a Medical care, Cost of |z United States | |
| 650 | 4 | |a Prescription pricing |x Government policy |z United States | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Elwin, Suzanna |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 1634633881 |z 9781634633888 |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029759724 | ||
Datensatz im Suchindex
| _version_ | 1804177601782087680 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV044357092 |
| collection | ZDB-4-NLEBK |
| ctrlnum | (ZDB-4-NLEBK)ocn899276755 (OCoLC)899276755 (DE-599)BVBBV044357092 |
| dewey-full | 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1 |
| dewey-search | 615.1 |
| dewey-sort | 3615.1 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04688nmm a2200541zc 4500</leader><controlfield tag="001">BV044357092</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170620s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634634151</subfield><subfield code="9">978-1-63463-415-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1634634152</subfield><subfield code="9">1-63463-415-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)ocn899276755</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)899276755</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044357092</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prescription drug prices paid under federal programs</subfield><subfield code="b">analyses, differences, factors</subfield><subfield code="c">edited by Suzanna Elwin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Nova Science Publishers</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Health care in transition series</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: PRESCRIPTION DRUGS: COMPARISON OF DOD, MEDICAID, AND MEDICARE PART DRETAIL REIMBURSEMENT PRICES; WHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; MEDICAID PAID LOWER NET PRICES THAN DOD ANDMEDICARE PART D, LARGELY DUE TO DIFFERENCES INPOST-PURCHASE PRICE ADJUSTMENTS; AGENCY COMMENTS; APPENDIX I: SCOPE AND METHODOLOGY.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Chapter 2: PRESCRIPTION DRUGS: COMPARISON OF DOD AND VADIRECT PURCHASE PRICESWHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; DOD PAID A HIGHER AVERAGE DIRECT PURCHASEPRICE THAN VA ACROSS THE ENTIRE SAMPLE BUT PAIDLESS THAN VA FOR BRAND-NAME DRUGS; CONCLUDING OBSERVATIONS; AGENCY COMMENTS AND OUR EVALUATION; APPENDIX I: SCOPE AND METHODOLOGY; APPENDIX II: RELATIVE PRICES PAID BY DOD AND VAFOR THE 83 DRUGS IN THE DIRECT PURCHASE SAMPLE; Chapter 3: PRESCRIPTION DRUGS: OVERVIEW OF APPROACHES TO CONTROL PRESCRIPTION DRUG SPENDING IN FEDERAL PROGRAMS; WHY GAO DID THIS STUDY.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">WHAT GAO FOUNDBACKGROUND; FEHBP USES COMPETITION BETWEEN HEALTH PLANSTO CONTROL PRESCRIPTION DRUG COSTS; OTHER FEDERAL PROGRAMS USE A RANGEOF APPROACHES TO CONTROL PRESCRIPTIONDRUG SPENDING; Chapter 4: MEDICAID PRESCRIPTION DRUGS:CMS SHOULD IMPLEMENT REVISEDFEDERAL UPPER LIMITS AND MONITORTHEIR RELATIONSHIP TO RETAILPHARMACY ACQUISITION COSTS*; WHY GAO DID THIS STUDY; WHAT GAO RECOMMENDS; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; CMS DEVELOPS NADACS BY SURVEYING RETAILCOMMUNITY PHARMACIES FOR INVOICE DATA ONACTUAL ACQUISITION COSTS.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">First quarter 2013 ppaca-based fulswere nearly equal to nadacs across alldrugs in aggregate, but varied greatlyfor individual drugsconclusion; recommendation for executive action; agency comments and our evaluation; appendix i.methodology for comparingfederal upper limits to national averagedrug acquisition costs; appendix ii. comparison of federalupper limits to national average drugacquisition costs, top 50medicaidexpenditure drugs; appendix iii. comparison of federal upper limitsto national average drug acquisition costs, top50medicaid utilization drugs</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">APPENDIX IV. 3-MONTH ROLLING AVERAGE FEDERALUPPER LIMITS COMPARED WITH NATIONAL AVERAGEDRUG ACQUISITION COSTSBlank Page; INDEX.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">In 2011, federal spending for prescription drugs by DOD, Medicaid, and Medicare Part D totaled 71.2 billion-representing about 85 percent of all federal prescription drug expenditures-for about 114.4 million beneficiaries. Each program reimbursed retail pharmacies for outpatient prescriptions filled at these pharmacies by their beneficiaries. This book compares retail reimbursement prices paid by DOD, Medicaid, and Medicare Part D for a sample of prescription drugs and describes factors affecting these prices. It also discusses approaches to control prescription drug spending in federal progra</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Prices</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health status indicators</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prescription pricing</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical care, Cost of</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prescription pricing</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prescription pricing / Government policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Politik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prescription pricing</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical care, Cost of</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prescription pricing</subfield><subfield code="x">Government policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elwin, Suzanna</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">1634633881</subfield><subfield code="z">9781634633888</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029759724</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV044357092 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:50:41Z |
| institution | BVB |
| isbn | 9781634634151 1634634152 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029759724 |
| oclc_num | 899276755 |
| open_access_boolean | |
| psigel | ZDB-4-NLEBK |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Nova Science Publishers |
| record_format | marc |
| series2 | Health care in transition series |
| spelling | Prescription drug prices paid under federal programs analyses, differences, factors edited by Suzanna Elwin New York Nova Science Publishers [2014] txt rdacontent c rdamedia cr rdacarrier Health care in transition series Includes index PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; PRESCRIPTION DRUG PRICES PAID UNDER FEDERAL PROGRAMS: ANALYSES, DIFFERENCES, FACTORS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: PRESCRIPTION DRUGS: COMPARISON OF DOD, MEDICAID, AND MEDICARE PART DRETAIL REIMBURSEMENT PRICES; WHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; MEDICAID PAID LOWER NET PRICES THAN DOD ANDMEDICARE PART D, LARGELY DUE TO DIFFERENCES INPOST-PURCHASE PRICE ADJUSTMENTS; AGENCY COMMENTS; APPENDIX I: SCOPE AND METHODOLOGY. Chapter 2: PRESCRIPTION DRUGS: COMPARISON OF DOD AND VADIRECT PURCHASE PRICESWHY GAO DID THIS STUDY; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; DOD PAID A HIGHER AVERAGE DIRECT PURCHASEPRICE THAN VA ACROSS THE ENTIRE SAMPLE BUT PAIDLESS THAN VA FOR BRAND-NAME DRUGS; CONCLUDING OBSERVATIONS; AGENCY COMMENTS AND OUR EVALUATION; APPENDIX I: SCOPE AND METHODOLOGY; APPENDIX II: RELATIVE PRICES PAID BY DOD AND VAFOR THE 83 DRUGS IN THE DIRECT PURCHASE SAMPLE; Chapter 3: PRESCRIPTION DRUGS: OVERVIEW OF APPROACHES TO CONTROL PRESCRIPTION DRUG SPENDING IN FEDERAL PROGRAMS; WHY GAO DID THIS STUDY. WHAT GAO FOUNDBACKGROUND; FEHBP USES COMPETITION BETWEEN HEALTH PLANSTO CONTROL PRESCRIPTION DRUG COSTS; OTHER FEDERAL PROGRAMS USE A RANGEOF APPROACHES TO CONTROL PRESCRIPTIONDRUG SPENDING; Chapter 4: MEDICAID PRESCRIPTION DRUGS:CMS SHOULD IMPLEMENT REVISEDFEDERAL UPPER LIMITS AND MONITORTHEIR RELATIONSHIP TO RETAILPHARMACY ACQUISITION COSTS*; WHY GAO DID THIS STUDY; WHAT GAO RECOMMENDS; WHAT GAO FOUND; ABBREVIATIONS; BACKGROUND; CMS DEVELOPS NADACS BY SURVEYING RETAILCOMMUNITY PHARMACIES FOR INVOICE DATA ONACTUAL ACQUISITION COSTS. First quarter 2013 ppaca-based fulswere nearly equal to nadacs across alldrugs in aggregate, but varied greatlyfor individual drugsconclusion; recommendation for executive action; agency comments and our evaluation; appendix i.methodology for comparingfederal upper limits to national averagedrug acquisition costs; appendix ii. comparison of federalupper limits to national average drugacquisition costs, top 50medicaidexpenditure drugs; appendix iii. comparison of federal upper limitsto national average drug acquisition costs, top50medicaid utilization drugs APPENDIX IV. 3-MONTH ROLLING AVERAGE FEDERALUPPER LIMITS COMPARED WITH NATIONAL AVERAGEDRUG ACQUISITION COSTSBlank Page; INDEX. In 2011, federal spending for prescription drugs by DOD, Medicaid, and Medicare Part D totaled 71.2 billion-representing about 85 percent of all federal prescription drug expenditures-for about 114.4 million beneficiaries. Each program reimbursed retail pharmacies for outpatient prescriptions filled at these pharmacies by their beneficiaries. This book compares retail reimbursement prices paid by DOD, Medicaid, and Medicare Part D for a sample of prescription drugs and describes factors affecting these prices. It also discusses approaches to control prescription drug spending in federal progra Drugs / Prices Health status indicators Prescription pricing MEDICAL / Pharmacology bisacsh Medical care, Cost of fast Prescription pricing fast Prescription pricing / Government policy fast Medizin Politik Prescription pricing United States Medical care, Cost of United States Prescription pricing Government policy United States USA Elwin, Suzanna Sonstige oth Erscheint auch als Druck-Ausgabe 1634633881 9781634633888 |
| spellingShingle | Prescription drug prices paid under federal programs analyses, differences, factors Drugs / Prices Health status indicators Prescription pricing MEDICAL / Pharmacology bisacsh Medical care, Cost of fast Prescription pricing fast Prescription pricing / Government policy fast Medizin Politik Prescription pricing United States Medical care, Cost of United States Prescription pricing Government policy United States |
| title | Prescription drug prices paid under federal programs analyses, differences, factors |
| title_auth | Prescription drug prices paid under federal programs analyses, differences, factors |
| title_exact_search | Prescription drug prices paid under federal programs analyses, differences, factors |
| title_full | Prescription drug prices paid under federal programs analyses, differences, factors edited by Suzanna Elwin |
| title_fullStr | Prescription drug prices paid under federal programs analyses, differences, factors edited by Suzanna Elwin |
| title_full_unstemmed | Prescription drug prices paid under federal programs analyses, differences, factors edited by Suzanna Elwin |
| title_short | Prescription drug prices paid under federal programs |
| title_sort | prescription drug prices paid under federal programs analyses differences factors |
| title_sub | analyses, differences, factors |
| topic | Drugs / Prices Health status indicators Prescription pricing MEDICAL / Pharmacology bisacsh Medical care, Cost of fast Prescription pricing fast Prescription pricing / Government policy fast Medizin Politik Prescription pricing United States Medical care, Cost of United States Prescription pricing Government policy United States |
| topic_facet | Drugs / Prices Health status indicators Prescription pricing MEDICAL / Pharmacology Medical care, Cost of Prescription pricing / Government policy Medizin Politik Prescription pricing United States Medical care, Cost of United States Prescription pricing Government policy United States USA |
| work_keys_str_mv | AT elwinsuzanna prescriptiondrugpricespaidunderfederalprogramsanalysesdifferencesfactors |